---
schema_version: "secwatch.filing_event.v1"
accession: "0001339970-26-000039"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2026-06-08T20:04:31+00:00"
generated_at: "2026-06-08T20:11:16.064224+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma receives Nasdaq extension to Nov 30, 2026 to cure bid price deficiency

## Summary
- Original bid price deficiency notice received Dec 4, 2025; stock closed below $1.00 for 30 consecutive days.
- On June 3, 2026, Nasdaq granted additional 180-day compliance period until November 30, 2026.
- Company must maintain closing bid price >= $1.00 for 10 consecutive business days to regain compliance.
- aTyr intends to cure deficiency via reverse stock split if necessary during second compliance period.
- Failure to regain compliance by Nov 30, 2026 may result in delisting from Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001339970-26-000039
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2026-06-08T20:04:31+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000039/0001339970-26-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000039/atyr-20260603.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001339970-26-000039
- JSON: https://secwatch.observer/filing/0001339970-26-000039.json
- Plain text: https://secwatch.observer/filing/0001339970-26-000039.txt

## Key facts
- Listing & Compliance Notices
  aTYR PHARMA INC received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: June 3, 2026, the Company received a letter from the Staff (the “Letter”) notifying the Company that the Company is eligible for an additional 180-day period, or until November 30, 2026 (the “Compliance Date”), to regain compliance, based on the Staff’s determination of the Company meeting the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement, and the Company’s written notice to Nasdaq of its intention to cure the deficiency during the second compl
  evidence_url: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000039/0001339970-26-000039-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.